This paper should contribute to the understanding of the pathological processes at the cellular level in malignant melanoma. Twenty-five melanoma cell lines were examined for different mutations and specific expression patterns. In addition, cell biological expression patterns and cell behavior were analyzed under the influence of the chemotherapeutic agent vemurafenib. It confirms the already known response of BRAF V600E mutant melanoma cells to treatment with vemurafenib. Cells that proved resistant to vemurafenib, despite the BRAF V600E mutation, had a specific expression pattern of receptor tyrosine kinases. The presence of the ErbB1 receptor precluded the expression of the ErbB3 receptor and vice versa. Furthermore, it was shown that in the absence of ErbB3 expression, the factor MIA is also expressed only to a small extent. On the other hand, cells expressing ErbB1 had almost no transcription factor MITF. Thus, there seems to be an undiscovered association between the expression pattern of ErbB1 and Erbb3 as well as the expression of MITF and MIA.